A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

Yoo, Dae‐Hyun; Hrycaj, Paweł; C. Miranda, Pedro; Ramiterre, Edgar; Piotrowski, Mariusz; Shevchuk, S.; Kovalenko, Volodymyr; Prodanović, Nenad; Abello-Banfi, Mauricio; Gutiérrez‐Ureña, Sergio; Morales-Olazabal, Luis; Tee, Michael; Jimenez, Renato; Zamani, Omid; Joon Lee, Sang; Kim, HoUng; Park, Won; Müller‐Ladner, Ulf

doi:10.1136/annrheumdis-2012-203090

Public

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

Published in Annals of the Rheumatic Diseases • May 18, 2013

Authors:

Dae‐Hyun Yoo

Paweł Hrycaj

Pedro C. Miranda

Abstract

OBJECTIVES: To compare the efficacy and safety of innovator infliximab (INX) and CT-P13, an INX biosimilar, in active rheumatoid arthritis patients with inadequate response to methotrexate (MTX) treatment. METHODS: Phase III randomised, double-blind, multicentre, multinational, parallel-group study....

Subject

Medicine

Rheumatoid arthritis

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!